Levinstein, Marjorie R. http://orcid.org/0000-0003-4360-1503
Ventriglia, Emilya N.
Gomez, Juan L.
Budinich, Reece C.
Marton, János
Henriksen, Gjermund
Holt, Daniel P.
Dannals, Robert F.
Pomper, Martin G.
Zarate, Carlos A. Jr
Bonaventura, Jordi http://orcid.org/0000-0002-4745-0151
Michaelides, Michael http://orcid.org/0000-0003-0398-4917
Article History
Received: 31 May 2022
Revised: 9 August 2022
Accepted: 11 August 2022
First Online: 23 August 2022
Declarations
:
: MM has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences. CAZ is listed as a coinventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as a coinventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. CAZ is listed as coinventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. CAZ has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors declare no conflicts of interest.